The retroviral myth of primary biliary cirrhosis: Is this (finally) the end of the story?  by Selmi, Carlo & Gershwin, M. Eric
412 Letters to the Editor / Journal of Hepatology 51 (2009) 411–415XiaoPing Pan
Haijun Huang
WeiBo Du
LanJuan Li *
Department of Infectious Diseases,
State key Laboratory for Diagnosis and Treatment of
Infectious Diseases, The First Aﬃliated Hospital of
Medical College, Zhejiang University,
Hangzhou, China
Department of Infectious Diseases,
The First Aﬃliated Hospital, School of Medicine,
Zhejiang University, 79 Qingchun Road,
Hangzhou 310003, China
* Tel.: +86 571 87236759; fax: +86 571 87236755.
E-mail address: ljli@zjwst.gov.cn (L. Li)
doi:10.1016/j.jhep.2009.04.006
The association of HBV core promoter double mutations (A1762T
and G1764A) with viral load diﬀers between HBeAg positive
and anti-HBe positive individuals: A longitudinal analysis – Reply
To the Editor:
Pan et al. [1] have expressed two concerns regarding
our study. First, although no study subjects received
antiviral therapy during the period of follow-up, some
individuals may have been treated prior to the study.
The members of the Long An cohort are low-income
agricultural workers unlikely to be able to aﬀord antivi-
ral drugs, and none reported their use when questioned
speciﬁcally at recruitment. Even if a few individuals had
received therapy previously, their viral loads should
have rebounded after the end of treatment and the lon-
gitudinal analysis carried out ensured that our results
would not have been inﬂuenced. Furthermore, the
diﬀerential eﬀects of BCP mutations on viral load in
HBeAg-positive and in HBeAg-negative patients have
been reported by other investigators [2]. The strength
of our study lies in the longitudinal analysis.
Their second point is that other factors, such as age,
sex and viral genotype, may have inﬂuenced the viral
loads. As stated in the methods Section 2.7.1 ‘Cross-sec-
tional analysis’, multiple linear regression analysis was
used to assess whether any diﬀerences detected remained
signiﬁcant after adjusting for HBeAg status and those
speciﬁc factors [3]. That was the case, although, for rea-
sons of brevity, those analyses were not detailed in the
paper. We do not consider that either of these issues
compromises our ﬁndings.
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The retroviral myth of primary biliary cirrhosis:
Is this (ﬁnally) the end of the story?
To the Editor:
The retroviral story of primary biliary cirrhosis
(PBC) has been enriched by a new episode in the
March issue of this Journal. In their article, Johal
and colleagues report their study of a large number
of liver samples taken from patients aﬀected by
doi:10.1016/j.jhep.2009.04.005
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PBC cases), at diﬀerent stages, with or without hepa-
tocellular carcinoma [1]. In all these samples, molecu-
lar methods were utilized to determine the presence of
the mouse mammary tumor virus-like virus (coined
MMTV-LV). There was no evidence of MMTV-LV
env protein in healthy liver tissues while a variable
proportion of samples with diﬀerent chronic diseases
manifested the presence of the virus. This proportion
(namely 3/26 for PBC) did not diﬀer among diﬀerent
etiologies, between early and advanced stages, or be-
tween neoplastic and non neoplastic tissues. While
we welcome a new group in the dichotomy which
has characterized the retroviral hypothesis of PBC,
we feel the necessity to raise some concerns on the
data and their interpretation.
The involvement of a retrovirus in the etiology of
PBC was ﬁrst proposed 11 years ago by Andrew Ma-
son’s group [2] and has since been supported by pub-
lications coming only from that group. This work has
more recently culminated in a pilot trial for antiretro-
viral therapies in patients with PBC in which putative
non validated endpoints (such as upper abdominal
pain) were included [3]. In 2004, we undertook an
unbiased and blinded eﬀort to determine the presence
of multiple MMTV molecular and tissue markers in a
large number of fresh liver and peripheral blood cells
from patients with PBC. We failed to identify any
proof of MMTV [4]; we note that Johal et al. failed
to cite subsequent editorials. Furthermore, we submit
that the work by Johal and colleagues has fatal and
naive ﬂaws and does not address crucial questions
arising from their results.
First, while stating that contaminations were
carefully avoided, the authors utilized both paraﬃn-
embedded and fresh liver tissues for DNA extraction,
thus including an obvious source of potential con-
tamination. Second, it is not established that the
molecular methods used have adequate sensitivity
for MMTV detection and suﬃcient speciﬁcity since
sequencing was performed in a minor group of posi-
tive cases. Third, the number of healthy controls is
clearly too limited to allow powerful comparisons gi-
ven the rarity of the virus in PBC samples. Fourth,
the authors have not attempted to explain the basis
for the discrepancies between the ﬁndings from the
three groups, including ours. Fifth and most impor-
tantly, the lack of association between etiology,
stage, or cancer fails to identify any possible working
theory behind the reported experimental observation.
There is still no biologic or immunologic plausibility.
The involvement of MMTV appears to be common
to all chronic liver diseases in minor percentages
and this clearly does not allow to formulate a
rational hypothesis to recapitulate the observation,
as suggested by experts in the ﬁeld of autoimmunity
[5].
For all the aforementioned reasons, we conclude
this letter with the same conclusion we arrived at in
2004 [6]. The retroviral story for PBC has been
around for almost a decade and no group has repro-
duced the original data nor developed any biologic
plausibility. We are all working together for the com-
mon goal of improved patient care. But let us remind
the readership of a saying attributed to Confucious:
‘‘Learning without thought is labor lost. Thought
without learning is perilous”.
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